Want to see APRE full AI Analyst Report?
APRE Stock Chart & Stats
$0.95
<$0.01(0.16%)
At close: 4:00 PM EDT
$0.95
<$0.01(0.16%)
Day’s Range― - ―
52-Week Range$0.55 - $1.69
Previous Close$0.61
Volume18.33K
Average Volume (3M)425.31K
Market Cap
$9.69M
Enterprise Value$2.40
Total Cash (Recent Filing)$41.23M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.31
Next Earnings
Nov 05, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding12,591,136
10 Day Avg. Volume130,888
30 Day Avg. Volume425,312
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.73Price Target Upside292.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.29
Revenue Forecast (FY)$817.00K
Bulls Say, Bears Say
Bulls Say
Intellectual Property ProtectionA broader patent estate can protect Aprea’s precision-oncology assets from direct competition and support future licensing or commercial opportunities. Potential exclusivity extending into 2047 gives clinical programs more time to generate value if efficacy is ultimately established.
APR-1051 Clinical ProgressExpanding trial enrollment and reported early activity provide tangible validation for the lead program, although development remains early. Progress across multiple biomarker-defined solid-tumor settings could broaden the addressable opportunity and improve the pipeline’s strategic relevance.
Funding RunwayThe stated cash runway gives Aprea time to advance clinical development without an immediate funding requirement, allowing milestones to accumulate before additional capital may be needed. This improves near-term execution flexibility despite the company’s ongoing development-stage losses.
Bears Say
No Recurring RevenueAprea has not demonstrated recurring product or partnership revenue, so its business currently lacks an operating earnings base. Until a candidate is approved or licensed, financial performance will remain dependent on clinical progress and external funding rather than customer demand.
Persistent Cash LossesOngoing operating and free-cash-flow deficits show that research and clinical activities are consuming substantial cash without offsetting inflows. This reduces financial self-sufficiency and means future development, regulatory work, and corporate operations may require continued capital access.
ATRN-119 Development SetbackPausing monotherapy development narrows the immediate advancement path for ATRN-119 and shifts the program toward less-established combination strategies. That change may delay clinical validation, increase development complexity, and leave greater reliance on APR-1051 as the lead value driver.
Aprea Therapeutics News
APRE FAQ
What was Aprea Therapeutics Inc’s price range in the past 12 months?
Aprea Therapeutics Inc lowest stock price was $0.55 and its highest was $1.69 in the past 12 months.
What is Aprea Therapeutics Inc’s market cap?
Aprea Therapeutics Inc’s market cap is $9.69M.
When is Aprea Therapeutics Inc’s upcoming earnings report date?
Aprea Therapeutics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 35 days.
How were Aprea Therapeutics Inc’s earnings last quarter?
Aprea Therapeutics Inc released its earnings results on Aug 12, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.178 by $0.108.
Is Aprea Therapeutics Inc overvalued?
According to Wall Street analysts Aprea Therapeutics Inc’s price is currently Undervalued.
Does Aprea Therapeutics Inc pay dividends?
Aprea Therapeutics Inc does not currently pay dividends.
What is Aprea Therapeutics Inc’s EPS estimate?
Aprea Therapeutics Inc’s EPS estimate is -0.07.
How many shares outstanding does Aprea Therapeutics Inc have?
Aprea Therapeutics Inc has 12,591,136 shares outstanding.
What happened to Aprea Therapeutics Inc’s price movement after its last earnings report?
Aprea Therapeutics Inc reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.178. Following the earnings report the stock price went up 3.485%.
Which hedge fund is a major shareholder of Aprea Therapeutics Inc?
Currently, no hedge funds are holding shares in APRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aprea Therapeutics Inc
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
APRE Stock 12 Month Forecast
Average Price Target
$3.73
▲(292.98% Upside)
Technical Analysis
Ownership Overview
6.39% Insiders
0.84% Mutual Funds
16.16% Other Institutional Investors
76.31% Public Companies and
Individual Investors